Myriad Genetics Inc (MYGN) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 
Myriad Genetics Inc   (NASDAQ: MYGN)
 

Myriad Genetics Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Myriad Genetics Inc inventory turnover ratio, the Myriad Genetics Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 8.66 in the third quarter 2026, MYGN's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Myriad Genetics Inc in Sep 30 2026 quarter, has decreased to 42 days, compare to 44 days, in the Jun 30 2026 quarter.

Within Healthcare sector 41 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 428 in the second quarter 2026, to 468.

MYGN Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Myriad Genetics Inc Market Share?

What is Inventory Turnover Ratio?




MYGN Inventory Turnover Ratio (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Inventory Growth -9.49 % 6.62 % -1.41 % 11.27 % 20.61 %
Y / Y Cost of Sales Growth 6.56 % 4.43 % 1.64 % 7.56 % -3.94 %
Inventory Turnover Ratio (TTM) 8.66 8.31 8.35 8.29 8.35
MYGN's Total Ranking # 468 # 428 # 275 # 275 #
Average inventory processing period 42 44 44 44 44
Seq. Inventory Growth -6.54 % 9.68 % -8.82 % -3.16 % 10.1 %
Seq. Cost of Sales Growth 2.04 % 2.74 % -3.13 % 4.92 % 0 %




Inventory Turnover Ratio Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 42
Overall Market # 468

Inventory Turnover Ratio Statistics
High Average Low
11.79 6.61 3.2
(Jun 30 2022)   (Jun 30 2017)




Financial Statements
Myriad Genetics Inc 's Inventories $ 29 Millions Visit MYGN's Balance sheet
Myriad Genetics Inc 's Cost of Revenues TTM $ 255 Millions Visit MYGN's Income Statement
What are MYGN's Sales? Visit MYGN's Sales by Segment

Other Inventory Turnover Ratios
Myriad Genetics Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
In Vitro & In Vivo Diagnostic Substances Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
MYGN's Inventory Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for MYGN's Competitors
Inventory Turnover Ratio for MYGN's Suppliers
Inventory Turnover Ratio for MYGN's Customers

You may also want to know
MYGN's Sales Growth Rates MYGN's Pe Price to earnings ratio MYGN's Receivables Turnover Ratio MYGN's Stock Quote
MYGN's Net Income Growth Rates MYGN's Ps Price to Sales ratio MYGN's Sales per Employee MYGN's Asset Turnover Ratio
MYGN's Net Margin MYGN's Pb Price to Book ratio MYGN's Financial Strength Ratios MYGN's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Teladoc Health Inc   23.99 $ 775.669  Millions$ 32  Millions
Adapthealth Corp   21.56 $ 2,649.368  Millions$ 123  Millions
Labcorp Holdings Inc   19.44 $ 10,367.400  Millions$ 533  Millions
Precipio inc   17.63 $ 15.391  Millions$ 1  Millions
Cryo cell International Inc   16.60 $ 6.680  Millions$ 0  Millions
Alnylam Pharmaceuticals Inc   12.28 $ 1,135.254  Millions$ 92  Millions
Brightspring Health Services Inc   11.57 $ 7,583.638  Millions$ 655  Millions
Tarsus Pharmaceuticals Inc   10.68 $ 49.325  Millions$ 5  Millions
Sotera Health Company  10.25 $ 558.509  Millions$ 54  Millions
Lantheus Holdings Inc   9.76 $ 604.826  Millions$ 62  Millions
Vanda Pharmaceuticals Inc   8.70 $ 14.704  Millions$ 2  Millions
Phathom Pharmaceuticals Inc   7.76 $ 53.106  Millions$ 7  Millions
Novavax inc   7.03 $ 90.533  Millions$ 13  Millions
Carlisle Companies Incorporated  6.99 $ 3,406.400  Millions$ 488  Millions
Cardiff Lexington Corporation  6.98 $ 3.768  Millions$ 1  Millions
Carlsmed Inc   6.91 $ 15.844  Millions$ 2  Millions
Caredx Inc   6.42 $ 111.106  Millions$ 17  Millions
Edap Tms Sa  6.14 $ 60.833  Millions$ 10  Millions
Transmedics Group Inc   5.70 $ 301.220  Millions$ 53  Millions
Bristol myers Squibb Company  5.65 $ 15,389.000  Millions$ 2,722  Millions
Avantor Inc   5.48 $ 4,539.200  Millions$ 828  Millions
Tactile Systems Technology Inc   5.25 $ 82.718  Millions$ 16  Millions
Integer Holdings Corporation  4.98 $ 1,376.268  Millions$ 276  Millions
Ge Healthcare Technologies Inc   4.69 $ 11,372.000  Millions$ 2,425  Millions
West Pharmaceutical Services Inc   4.69 $ 2,120.200  Millions$ 452  Millions
Henry Schein Inc   4.63 $ 9,395.000  Millions$ 2,031  Millions
Cryoport inc   4.60 $ 102.157  Millions$ 22  Millions
Myomo Inc   4.58 $ 14.802  Millions$ 3  Millions
Idexx Laboratories Inc  4.52 $ 1,743.379  Millions$ 386  Millions
Autolus Therapeutics Plc  4.34 $ 88.293  Millions$ 20  Millions

Date modified: 2026-11-07T13:15:45+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.